Mayo clinic tests 'Senolytic' drugs in bid to target aging cells in Alzheimer's
NCT ID NCT04785300
Summary
This small, early-stage study aims to see if a combination of two existing drugs, Dasatinib and Quercetin, is safe and practical for people with mild cognitive impairment or Alzheimer's disease. The drugs target 'senescent' cells, which are old, damaged cells that may contribute to aging and disease. The study will enroll about 20 participants over 55 to monitor for side effects and how well they tolerate the treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
Conditions
Explore the condition pages connected to this study.